{"name":"Smilebiotek Zhuhai Limited","slug":"smilebiotek-zhuhai-limited","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"QA108 granules","genericName":"QA108 granules","slug":"qa108-granules","indication":"Treatment of irritable bowel syndrome (IBS)","status":"phase_3"}]}],"pipeline":[{"name":"QA108 granules","genericName":"QA108 granules","slug":"qa108-granules","phase":"phase_3","mechanism":"QA108 granules are a gut microbiome modulator.","indications":["Treatment of irritable bowel syndrome (IBS)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi2wFBVV95cUxNSXdPV2lscUhwTkFpQUJlMHBoVkFwak5DblZOdjVlVGZhNXRWNVItSVdyM2wyYzdGLV85dWJsY0xOdWFicXpZT1owQ0pBRVZjZTMwMzBTUUxjRkpwLVAxa1VWYVFMYVh2dFZ1SnI1ek44V0NGQ1M4amRxNHlSNkg4eG1uU25QLUwyOXExSnU2MkFzREZNX0std2pQNXJPWGQ0aHNaVUs5N1lneXZXaWVlaklNaWRlTnN0VXJBMWxsWVhPNmtpQTd3M3REVmdEZWxiMEpfTDBsYnU1Z2c?oc=5","date":"2024-08-02","type":"pipeline","source":"BioSpace","summary":"Dry Age Macular Degeneration (Dry AMD) Market to Reach a CAGR of 4.64% during 2024-2034, Impelled by Anti-Angiogenic Drugs - BioSpace","headline":"Dry Age Macular Degeneration (Dry AMD) Market to Reach a CAGR of 4.64% during 2024-2034, Impelled by Anti-Angiogenic Dru","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}